Global Antibiotic R&D Partnership (GARDP)

Around 600 babies in Kenya will take part in this landmark trial, which also forms part of the EU funded, Penta-led SNIP-AFRICA consortium which aims to reduce mortality among newborns with sepsis in African hospitals.

📢 NEWS: Kenya joins GARDP’s NeoSep1 Part 2 trial on #NeonatalSepsis.

The trial has started enrolling newborn babies with sepsis at Kilifi County Hospital (Kilifi) Coast General Teaching & Referral Hospital (Mombasa) and Mbagathi Hospital (Nairobi).

Published during the Munich Security Conference, Manica Balasegaram’s op-ed in The Telegraph explains how conflict, climate change and global instability are driving the rise of drug-resistant infections, and why AMR must be part of the discussions.

🔗 bit.ly/3OgF0qy

@telegraph.co.uk

“This recognition belongs to everyone at GARDP and to the extraordinary network of partners, donors, researchers, trial participants and country teams who made this public-private partnership possible,” said Dr Balasegaram.

TIME highlights GARDP’s central role in advancing zoliflodacin, a first-in-class treatment for uncomplicated urogenital gonorrhoea approved by the US FDA in December 2025.

🔗 GARDP statement: gardp.org/dr-manica-ba...

#GlobalHealth #AntimicrobialResistance

This recognition reflects years of collective work at GARDP to develop new antibiotics through a not-for-profit model focused on equitable access.

🌍🏆 Dr Manica Balasegaram has been named one of TIME’s 100 most influential people in health for advancing and expanding access to new antibiotic treatments so as to tackle antimicrobial resistance.

🔗 Read the TIME feature: time.com/collections/...

#TIME100

👩 On the International Day of Women and Girls in Science, Astrid Pentz-Murr reflects on how women’s scientific leadership strengthens antibiotic R&D and drives real public health impact.

At GARDP, supporting women in science is central to advancing better solutions to #AMR.

@astridpm.bsky.social

📢 Hiring

GARDP is looking for a senior medical leader to develop and lead its Medical Sciences function and to shape and deliver medical science strategy across an assigned disease area and portfolio.

📍 Switzerland, UK or Spain (non-US)

🔗 Apply: https://gardp.pulse.ly/63tnadztca

#Careers

🧬A new #REVIVE viewpoint explores the ongoing challenges in treating carbapenem-resistant Acinetobacter baumannii, outlining where therapies fall short and what’s needed next to improve patient outcomes.

🔗 Read more: revive.gardp.org/managing-aci...

🌍📄 GARDP welcomes the development of a new Global Action Plan on AMR that places research, development and access at the core of its objectives.

On behalf of GARDP, Philip Kenol of @dndi.org delivered our statement at the @who.int Executive Board, 158th session.

Watch the clip🔽

🎉🧬 That’s a wrap on #ACC2026

An incredible and a valuable space for the AMR community to connect, exchange evidence and reflect on what comes next.

Thank you all for the energy and ideas.

See you next year!

🔗Register to watch the recorded sessions and more: acc-conference.com#registration

🚩 A strong close to ACC2026

Panelists underscored the need for better tools, better data and better systems — from WHO-led frameworks to the AWaRe classification to digital visibility across antibiotic use.

💥🔴 This hit home

Dr Manica Balasegaram connects the dots between missing evidence and weak stewardship, reminding us that access without data can quickly undermine innovation.

🔗Head to the discussion now: bit.ly/3LVHIkF

#ACC2026

💊When antibiotics are named generically, misuse follows.

Dr Jeffrey Smith explains how poorly performing, fragmented access systems and generic antibiotic guidance can lead to inappropriate use and lost impact.

🔗The session is still LIVE: bit.ly/3LVHIkF

#ACC2026

🌍🔬 From the closing panel

Access without stewardship risks losing new antibiotics fast. Dr Anita Kotwani points to practical global frameworks that help strengthen antibiotic use and stewardship in primary care settings, particularly in LMICs.

🎥 Join live now: bit.ly/3LVHIkF

#ACC2026

🔴🚨 FINAL SESSION IS LIVE at #ACC2026

Title: Access isn’t the end, it’s the beginning.

Our closing panel takes on the purpose of antimicrobial innovation, and what must come after access.

🔴 WATCH IT LIVE NOW: portalapp.bsac.eventsair.com/VirtualAtten...

🎯The key takeaway:

“Antibiotics don’t see age, but prescribers do.”

Prof Julia Bielicki drives home why neonates and children are not small adults, and why tiny doses carry big stakes for safety, efficacy and long-term outcomes.

👀Watch the final session of #ACC2026: bit.ly/3LVHIkF

🔴💥 Session Seven moment

“From erections to resurrection — not womb to tomb.”

With that striking opening, Dr Teodora Elvira C. Wi reframes the conversation on STIs, maternal infections and neonatal sepsis, and why early action matters.

🎦Watch the rest of the session LIVE: bit.ly/3LVHIkF

#ACC2026

Dr Sumati Nambiar explains why pregnant women must be ethically and safely included in antimicrobial clinical trials — and why the current evidence gap puts both mothers and babies at risk.

🔗 bit.ly/3LVHIkF

#ACC2026

🔴🚨 Happening LIVE right now

From womb to world, this session tackles one of the most urgent gaps in AMR: how we design, test and deliver antimicrobials for pregnant women, newborns and children.

🔗Tune in live now: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026

⚡That’s a wrap on Session Six

A strong finish with new data on fungal colonisation in critical care, followed by an active and thoughtful Q&A with the audience.

⏳ Break time now — but don’t go far. We’re back LIVE soon with Session Seven: From womb to world.

🔗 bit.ly/4rayyzO

#ACC2026

We’ve just heard rapid-fire insights on S. aureus persistence and new strategies against Gram-negative pathogens — and one final oral poster is coming up next.

👀 See it live: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026

⭐Session Six highlights

Oral posters opened with data on AMR-related illness and death in advanced HIV, and co-resistance trends in uropathogenic E. coli and Klebsiella

🎥Three more posters to go, watch them live: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026

🪧Now live | Session Six at #ACC2026

This session features rapid-fire oral poster presentations highlighting emerging data and new insights across antimicrobial resistance and infectious diseases research.

👉 Watch live: portalapp.bsac.eventsair.com/VirtualAtten...

🔚✨ Session Five has just concluded at #ACC2026

Thank you to the speakers for an engaging discussion on the clinical development and use of new agents.

Up next: Session Six – Oral poster presentations, starting shortly.

🔗Join the new session: portalapp.bsac.eventsair.com/VirtualAtten...

Dr Jeremy Dennison dives into the clinical development of GSK's gepotidacin, a novel oral antibiotic targeting uncomplicated UTI, sharing rich detail on its mechanism, data and potential role in care.

It's an energizing one!

🎥 Catch it live: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026

Chlamydia is the most common sexually transmitted bacterial disease in the world. Dr Alvaro Borges reports about the progress in the development of a vaccine to prevent chlamydia infections.

🔥 On stage now!

Dr Alvaro Borges begins his presentation sharing updates on Chlamydia trachomatis vaccine development and what it could mean for future control strategies and progress in the field.

▶️ Join live now: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026

Cutting-edge clinical development is in focus, starting with a new combination targeting A. baumannii, we'll move onto novel approaches addressing chlamydia infections and a brand-new antibiotic for treating UTIs.

🎥 Watch live now: portalapp.bsac.eventsair.com/VirtualAtten...

#ACC2026 #AMR